|

Alzheimer's Disease Clinical Trials in Connecticut

14 recruiting studies across 5 cities

All Trials in Connecticut

Phase
Trial Phase Location
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)Phase 3Farmington
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)Phase 3Farmington
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)Phase 2New Haven
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic MutationPhase 2/3New Haven
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic MutationPhase 2/3New Haven
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR VariantPhase 3New Haven
Evaluation of a Mobile App Program for Coping With CancerN/ANew Haven
Exploring the Utility of [18F]3F4AP for Demyelination ImagingPhase 1New Haven
Music for Pain and DementiaN/ANew Haven
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease StudiesPhase 3New Haven
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's DiseasePhase 3Norwalk
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)Phase 2Stamford
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)Phase 3Stamford
Neurologic Stem Cell Treatment StudyN/AWestport

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.